Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449666 | 0.85 | MAPT (0.59) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5436770 | 0.84 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5444864 | 0.83 | KDM4E (0.47) | KMT2AKDRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5439554 | 0.83 | BLM (0.55) | MEN1KMT2AKDRSMN1; SMN2NPC1 | |
| SCHEMBL5444881 | 0.82 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5444618 | 0.81 | RAF1 (0.54) | MEN1KMT2AKDRSMN1; SMN2NPC1 | |
| SCHEMBL5447930 | 0.81 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5454319 | 0.80 | MEN1 (0.62) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5435490 | 0.76 | LMNA (0.58) | MEN1KMT2APDGFRAKDRSMN1; SMN2 | |
| SCHEMBL6378070 | 0.69 | MAPT (0.61) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | MEN1 1756/4885KMT2A 1865/4885PDGFRA 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.